|
Volumn 42, Issue 9, 2010, Pages 3471-3474
|
The clinical importance of flow cytometry crossmatch in the context of CDC crossmatch results
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ARTICLE;
B LYMPHOCYTE;
BLOOD GROUP TYPING;
CYTOTOXICITY TEST;
FLOW CYTOMETRY;
FLOW CYTOMETRY CROSSMATCH;
GRAFT SURVIVAL;
HUMAN;
KIDNEY DONOR;
KIDNEY GRAFT;
LIVING DONOR;
MAJOR CLINICAL STUDY;
PRIORITY JOURNAL;
RISK FACTOR;
T LYMPHOCYTE;
ANTIBODIES;
B-LYMPHOCYTES;
CYTOTOXICITY TESTS, IMMUNOLOGIC;
FLOW CYTOMETRY;
GRAFT REJECTION;
GRAFT SURVIVAL;
HISTOCOMPATIBILITY TESTING;
HUMANS;
KAPLAN-MEIER ESTIMATE;
KIDNEY TRANSPLANTATION;
LIVING DONORS;
PREDICTIVE VALUE OF TESTS;
PROPORTIONAL HAZARDS MODELS;
REGISTRIES;
RISK ASSESSMENT;
RISK FACTORS;
SENSITIVITY AND SPECIFICITY;
T-LYMPHOCYTES;
TIME FACTORS;
TISSUE AND ORGAN PROCUREMENT;
TREATMENT OUTCOME;
UNITED STATES;
|
EID: 78649475238
PISSN: 00411345
EISSN: None
Source Type: Journal
DOI: 10.1016/j.transproceed.2010.06.025 Document Type: Article |
Times cited : (29)
|
References (7)
|